Implications of Food and Drug Administration Approval of Respiratory Syncytial Virus Prophylactic Medication
- Ashley Saint-Fleur; Catherine Kier
Access Resources
About
This brief article discusses the implications of the FDA approval of nirsevimab, a monoclonal antibody, for preventing respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in infants and toddlers. RSV is a common cause of LRTIs and hospitalizations among young children. The approval of nirsevimab expands preventive therapies for RSV, especially benefiting high-risk infants. This approval marks progress in combating RSV-related illnesses in vulnerable populations.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.